Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Medicina (Kaunas, Lithuania)|May 4, 2026
PEACE: Development and Validation of a Brief Five-Item Sleep Quality Scale for Community and Primary CareGiuseppe Di Lorenzo, Luca Scafuri, Francesco Passaro, et al.
Journal of Basic and Clinical Physiology and Pharmacology|January 3, 2026
Serum copper, rubidium, selenium, strontium, and zinc and psychophysical health in adults of the Sarno river Basin: PREVES-STOP 2025 community biomonitoring resultsLuca Scafuri, Raffaele Baio, Carlo Buonerba, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 5, 2022
Germline rare variants of lectin pathway genes predispose to asymptomatic SARS-CoV-2 infection in elderly individualsGiuseppe D'Alterio, Vito Alessandro Lasorsa, Ferdinando Bonfiglio, et al.
Clinical Genitourinary Cancer|May 7, 2021
Assessment of Total, PTEN-, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving EnzalutamideGiuseppe Di Lorenzo, Silvia Zappavigna, Felice Crocetto, et al.
Oncology|September 29, 2025
Development and Validation of the PREVES-HOR Questionnaire: A Patient-Reported Measure of Hormone Therapy-Related Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation TherapyGiuseppe Di Lorenzo, Antonio Verde, Luca Scafuri, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology NetworkMarilena Di Napoli, Elisabetta Coppola, Carmine D'Aniello, et al.
Oncotarget|May 8, 2018
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN studyJacob A Gordon, Carlo Buonerba, Gregory Pond, et al.
Urologic Oncology|September 20, 2025
The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG): Analysis of USA insurance claim dataFrancesco Del Giudice, Valerio Santarelli, Jan Łaszkiewicz, et al.
Medicine|October 27, 2015
Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter ExperienceMatteo Ferro, Ottavio De Cobelli, Carlo Buonerba, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCGCarlo Buonerba, Raffaele Baio, Felice Crocetto, et al.
Pageof 16